Linagliptin Viatris

Linagliptin, the active ingredient in Linagliptin Viatris, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as an oral tablet for oral use. It is employed to improve blood glucose control in adults with type 2 diabetes mellitus and may be used as part of a comprehensive treatment plan.

GNH USA supplies Linagliptin Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide with a focus on quality assurance, regulatory compliance and reliable global logistics. Our network ensures timely delivery and support for healthcare providers across diverse markets. We adhere to stringent Good Distribution Practice standards to maintain product integrity.

Linagliptin is a DPP‑4 inhibitor used to manage hyperglycaemia in type 2 diabetes. - Type 2 diabetes mellitus (monotherapy): lowers fasting and post‑prandial glucose when added to diet and exercise. - Type 2 diabetes mellitus (combination therapy): used with metformin, sulfonylureas or insulin to improve overall glycaemic control. - Type 2 diabetes mellitus (adjunct therapy): enhances insulin secretion and reduces glucagon release as part of a comprehensive treatment regimen.

Linagliptin may be associated with several adverse reactions, ranging from mild to serious. Common Side Effects: - Upper respiratory tract infection: nasopharyngitis, sinusitis or cough. - Headache: mild to moderate intensity. - Gastrointestinal discomfort: nausea, abdominal pain or dyspepsia. Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain with vomiting. - Severe hypersensitivity: rash, angioedema or anaphylaxis. - Hepatic enzyme elevation: significant increase in ALT/AST.

Before prescribing Linagliptin, clinicians should consider several safety aspects and patient-specific factors. - Renal impairment: dose adjustment is not required, but monitor renal function regularly. - Hepatic disease: use with caution and assess liver enzymes periodically. - Cardiovascular risk: evaluate for heart failure history, although no direct contraindication. - Concomitant medications: review for potential drug interactions, especially with strong CYP3A4 inhibitors. - Pregnancy and lactation: avoid use due to insufficient safety data. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original packaging.

Linagliptin can interact with other medicines, affecting its efficacy or safety. Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase linagliptin exposure. - Combined use with other DPP‑4 inhibitors: additive effect on glucose lowering, risk of hypoglycaemia. Moderate Interactions (Monitor Closely): - Diuretics (e.g., thiazides): may enhance risk of dehydration and renal effects. - Insulin or sulfonylureas: increased hypoglycaemia potential; dose adjustments may be needed. - Rifampicin: may reduce linagliptin plasma levels, decreasing efficacy.